Eil. Ashforth et al., THE PHARMACOKINETICS OF ONDANSETRON AFTER INTRAVENOUS-INJECTION IN HEALTHY-VOLUNTEERS PHENOTYPED AS POOR OR EXTENSIVE METABOLIZERS OF DEBRISOQUINE, British journal of clinical pharmacology, 37(4), 1994, pp. 389-391
The pharmacokinetics of the 5-HT3 receptor antagonist ondansetron foll
owing an 8 mg i.v. dose were investigated in 12 subjects previously ph
enotyped with debrisoquine. Six subjects were poor metabolisers (debri
soquine metabolic ratios 29-131) and six were extensive metabolisers (
debrisoquine metabolic ratios 0.45-3.4). There was no significant diff
erence in AUC, C(max), CL or t1/2 between the poor and extensive metab
olisers. It is concluded that ondansetron clearance is not mediated ex
clusively by cytochrome P-450 2D6.